Endometrial cancer (EC) is the most common cancer of the female reproductive organs in the US. The unfortunate truth, despite this face, is that Black women may not understand the significant health concern EC poses for us specifically. The stark reality is undeniable: Black women are not only more likely to be diagnosed with endometrial cancer, but we’re twice as likely to lose our lives to this disease compared to other racial and ethnic groups. It’s a statistic that’s as shocking as it is disheartening. So, why is this happening?
While it is a very complex question, one of the answers lies in a glaring oversight: the underrepresentation of Black women in endometrial cancer research. Clinical trials, the very foundation of medical advancements, often fail to include a diverse group of participants. This lack of diversity can lead to treatments that may not be as effective for Black women. It’s not about race-based treatments, but about ensuring that our unique experiences and biological differences are reflected in the research that shapes our healthcare.
Our genes are not one-size-fits-all. Genetic variations can impact how different populations respond to treatments. By including a diverse range of participants in clinical trials, researchers can unlock the secrets of personalized medicine, tailoring treatments to specific genetic backgrounds. But it’s also not just about genetics. Cultural factors, like diet, lifestyle, and healthcare access, play a crucial role in cancer risk and outcomes. By incorporating individuals from diverse backgrounds, we can ensure that research findings truly benefit everyone, not just a select few.
It’s no secret that many people, especially those from marginalized communities—and specifically Black people—have a deep-rooted distrust of the medical establishment. Historical injustices such as unethical medical experiments and discriminatory practices are hard to forget. And when it comes to clinical research, this distrust is proving to be a roadblock to progress. If we remain hesitant to participate in clinical trials, it will absolutely limit the diversity and the development of treatments that are effective for everyone.
This is not to say the advancement in EC lies on the backs of Black women (we’ve done enough, haven’t we?). Researchers must foster open communication and build our trust to overcome these barriers and ensure clinical research benefits everyone. It is also important to remember that clinical research has evolved in terms of ethics. Today, regulatory oversight, informed consent processes, and protections for vulnerable populations (pregnant women, children, elderly, disabled, etc.) are in place to ensure that research is conducted ethically and responsibly.
All things considered, endometrial cancer is a significant health concern for Black women, and we must address this issue through increased awareness, improved access to care, and greater diversity in clinical research. By understanding the risks, seeking early detection, and advocating for inclusive research, we can empower Black women to take control of our health and work towards a future where this disease no longer disproportionately affects our community.
by Tiffany Drummond, ECANA Advisor and Patient Advocate
